CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Cryoablation for Prostate Cancer Policy

Policy for coverage of percutaneous cryoablation (cryoablation/cryotherapy/cryosurgery) of the prostate for Commercial Products only; addresses use as initial treatment or salvage therapy after radiation for clinically localized (organ-confined) prostate cancer and coding/diagnosis guidance.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCryoablation for Prostate Cancer Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDocument that prostate cancer is clinically localized (organ-confined) and whether cryoablation is being used as initial therapy or as salvage therapy after radiation; applicable to Commercial Products only.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes noted in this update.

2Covered Treatment Contexts

4Covered ICD-10 Codes Listed

Coverage Summary

Scope: Policy for coverage of percutaneous cryoablation (cryoablation/cryotherapy/cryosurgery) of the prostate for Commercial Products only; addresses use as initial treatment or salvage therapy after radiation for clinically localized (organ-confined) prostate cancer. (Coverage stance: covered_with_criteria for Cryoablation for Prostate Cancer.)

Medical-Necessity Criteria

Medically Necessary Indications

Cryoablation of the prostate is considered medically necessary when the following conditions are met:

ALL of the following

Procedure is percutaneous cryoablation (whole-gland/total cryoablation).
Diagnosis is clinically localized (organ-confined) prostate cancer.
Treatment context
- Initial treatment: Performed as initial treatment for clinically localized (organ-confined) prostate cancer.
- Salvage treatment: Performed as salvage treatment for disease that recurs following radiation therapy.
Plan applicability: Applicable to Commercial Products only (policy not governing BlueCHiP for Medicare; refer to related Medicare policy).

ref

title

title_raw

nodes_raw

Not Covered / Emerging Techniques

Subtotal (focal) cryoablation is described as an emerging technique and is not included among the whole-gland indications identified as medically necessary in this policy. The background frames subtotal/focal approaches as experimental/emerging and distinguished from the whole-gland (total) cryoablation indications reviewed for initial and salvage use.

Provider Actions

Documentation Required

Confirm indication and treatment context

Document that prostate cancer is clinically localized (organ-confined) and whether cryoablation is being used as initial therapy or as salvage therapy after radiation; applicable to Commercial Products only.

Affected diagnosis codes: C61, C79.82, D07.5, Z85.46
Applies to Commercial Products only

Billing Rule

File with covered diagnosis

Report CPT code 55873 when filed with one of the covered ICD-10 diagnoses listed; claims should be submitted under Commercial Products benefit.

Affected CPT code: 55873
Submit claims under Commercial Products benefit

Background

Cryoablation (also called cryotherapy or cryosurgery) treats prostate cancer by percutaneously inserting thin, needle-like cryoprobes into the prostate gland and delivering very cold gas to rapidly freeze and thaw tissue, causing necrosis. Most studies evaluate total (whole-gland) cryoablation, and this policy reviews evidence for whole-gland cryoablation when used as initial definitive therapy and as salvage treatment after radiation for clinically localized (organ-confined) prostate cancer.

The review notes that subtotal (focal) cryoablation and alternative procedures are considered separately and are an emerging approach; salvage treatment after radiotherapy has fewer treatment options and prostatectomy can be difficult in irradiated tissue.

Available evidence for whole-gland cryoablation includes several systematic reviews, randomized controlled trials, and multiple comparative and noncomparative observational studies. While high-quality direct comparisons with external-beam radiotherapy, radical prostatectomy, or active surveillance are limited, available data have suggested similar overall and disease-specific survival compared with radical prostatectomy and external-beam radiotherapy for initial therapy, and the evidence is judged sufficient to determine a meaningful improvement in net health outcome for whole-gland cryoablation in the indicated settings. For salvage cryoablation after radiotherapy, evidence is primarily noncomparative case series and some retrospective comparative studies, with mixed high-quality data versus prostatectomy but overall considered sufficient for a meaningful improvement in net health outcome in that context.

Name	Type/Number
Focal Treatments for Prostate Cancer	NCD